The lipid triad, or how to reduce residual cardiovascular risk?

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Statins significantly reduce cardiovascular events by lowering LDL cholesterol.
• Despite widespread statin use, a high residual vascular risk remains in certain patient groups.
• This residual risk is linked to atherogenic dyslipidemia, characterized by low HDL, high triglycerides, and small, dense LDL particles, often seen in metabolic syndrome and diabetes.

Purpose of the Study:

• To highlight the persistent challenge of residual vascular risk in cardiovascular disease prevention.
• To emphasize the need for a comprehensive lipid management strategy beyond LDL reduction.
• To underscore the importance of addressing low HDL and high triglycerides, particularly in patients with metabolic abnormalities.

Main Methods:

• Review of large prospective trials on statin efficacy.
• Analysis of lipid profiles associated with residual vascular risk.
• Examination of the prevalence of metabolic abnormalities contributing to atherogenic dyslipidemia.

Main Results:

• Statins achieve 25-35% reduction in major cardiovascular events.
• A significant residual vascular risk persists, especially in patients with the 'lipid triad' (low HDL, high triglycerides, small dense LDL).
• The increasing prevalence of metabolic syndrome and type 2 diabetes exacerbates this issue, questioning recent cardiovascular prevention gains.

Conclusions:

• Current lipid management focusing solely on LDL reduction is insufficient.
• A multi-parameter approach is necessary, including lowering LDL and triglycerides, and increasing HDL cholesterol.
• Further research and novel therapeutic compounds, particularly those enhancing HDL, are crucial for improving cardiovascular outcomes.